Atypical opioids
Keywords:
atypical opioids, chronic pain managementAbstract
Opiates and opioids remain the main pillars of analgesia. Their use is, however, limited by abuse potential as well as their side effect profile. Thus, there is a need for the development of newer opioids. The atypical opioids tramadol, tapentadol, dextromethorphan (DXM), and buprenorphine are newer synthetic opioids. These opioids do not solely depend on mu-receptor agonism for their analgesic effects. Except for DXM, atypical opioids are now being used more than conventional opioids as part of chronic pain management.
Downloads
Published
Issue
Section
License
By submitting manuscripts to SAJAA, authors of original articles are assigning copyright to the SA Society of Anaesthesiologists. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJAA for educational and research purposes without obtaining permission.
The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License. The SAJAA does not hold itself responsible for statements made by the authors.